0000950142-20-000321.txt : 20200206 0000950142-20-000321.hdr.sgml : 20200206 20200206170400 ACCESSION NUMBER: 0000950142-20-000321 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200206 DATE AS OF CHANGE: 20200206 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: APPLIED DNA SCIENCES INC CENTRAL INDEX KEY: 0000744452 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380] IRS NUMBER: 592262718 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-78682 FILM NUMBER: 20583478 BUSINESS ADDRESS: STREET 1: 50 HEALTH SCIENCES DRIVE CITY: STONY BROOK STATE: NY ZIP: 11790 BUSINESS PHONE: 631-240-8800 MAIL ADDRESS: STREET 1: 50 HEALTH SCIENCES DRIVE CITY: STONY BROOK STATE: NY ZIP: 11790 FORMER COMPANY: FORMER CONFORMED NAME: PROHEALTH MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 20010504 FORMER COMPANY: FORMER CONFORMED NAME: DCC ACQUISITION CORP DATE OF NAME CHANGE: 19990211 FORMER COMPANY: FORMER CONFORMED NAME: DATALINK CAPITAL CORP/TX/ DATE OF NAME CHANGE: 19980306 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Grossman Bruce CENTRAL INDEX KEY: 0001638139 FILING VALUES: FORM TYPE: SC 13G/A MAIL ADDRESS: STREET 1: C/O DILLON HILL CAPITAL LLC STREET 2: 200 BUSINESS PARK DRIVE, SUITE 306 CITY: ARMONK STATE: NY ZIP: 10504 SC 13G/A 1 eh2000268_13ga1-adna.htm AMENDMENT NO. 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Applied DNA Sciences, Inc.
(Name of Issuer)
 
Common Stock
(Title of Class of Securities)
 
03815U201
(CUSIP Number)
 
December 31, 2019
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 
☐ 
Rule 13d-1(b)
 
☒ 
Rule 13d-1(c)
 
☐ 
Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 03815U201
SCHEDULE 13G
Page 2 of 6
 
 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 
Bruce Grossman
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)  ☐
(b)  ☐
3
SEC USE ONLY
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
USA
 
NUMBER OF
SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
254,400
6
SHARED VOTING POWER
 
100,000
7
SOLE DISPOSITIVE POWER
 
254,400
8
SHARED DISPOSITIVE POWER
 
100,000
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
354,400
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
☐
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
9.9%
 
12
TYPE OF REPORTING PERSON
 
IN
 



CUSIP No. 03815U201
 SCHEDULE 13G
Page 3 of 6
 
 
Item 1.
(a)
Name of Issuer
  Applied DNA Sciences, Inc.
     
 
(b)
Address of Issuer’s Principal Executive Offices
   
50 Health Sciences Drive
   
Stony Brook, New York 11790
   
Item 2.
(a)
Name of Person Filing
   
Bruce Grossman (the “Reporting Person”)
 
 
(b)
Address of Principal Business Office or, if none, Residence
   
c/o Dillon Hill Capital LLC
200 Business Park Drive, Suite 306
Armonk, NY 10504
   
 
 
(c)
Citizenship
    USA 
 
 
 
 
(d) 
Title of Class of Securities
   
See cover page
   
 
  (e)  CUSIP Number 
 
 
See cover page
 
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
 
 
(a)
 [__] 
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
 
(b)
 [__] 
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c)
 
(c)
 [__] 
Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)
 
(d)
 [__] 
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
 
(e)
 [__] 
An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E)
 
(f)
 [__] 
An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);
 
(g)
 [__] 
A Parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);
 
(h)
 [__] 
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
 
(i)
 [__] 
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
 
(j)
 [__] 
Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
 

CUSIP No. 03815U201
 SCHEDULE 13G
Page 4 of 6
 
Item 4.                  Ownership
The shares of Common Stock reported on this Schedule are indirectly beneficially owned by the Reporting Person.

Dillon Hill Capital, LLC, of which the Reporting Person is the sole member, directly owns: (i) $1,500,000 principal amount of secured convertible notes (the “Notes”) that are convertible into 69,444 shares of Common Stock of the Issuer, (ii) 185,000 shares of Common Stock of the Issuer and (iii) warrant to purchase up to 401,000 shares of Common  stock of the Issuer (the “Warrants”).

Dillon Hill Investment Company LLC, the sole member of which is a trust of which the Reporting Person’s spouse is the co-trustee, directly owns 100,000 shares of Common Stock and 513,739 Warrants.

The Reporting Person may be deemed to have sole voting and dispositive power over shares, Notes and Warrants held by Dillon Hill Capital LLC and shared voting and dispositive power over the shares and Warrants held by Dillon Hill Investment Company LLC.

The Notes and the Warrants include a provision limiting conversion of the Notes and exercise of the Warrants to the extent that conversion or exercise would result in the Reporting Person beneficially owning more than 9.99% of the Issuer’s Common Stock.  As a result, the conversion of the Notes and the exercise of the Warrants by the Reporting Person may be limited and the amounts shown in Items 5 through 9 of the cover page to this schedule reflect only the Common Stock held by the Reporting Person and the Common Stock issuable upon conversion of the Notes. 

The percentage beneficial ownership reported in Item 11 of the cover pages to this Schedule was calculated based on 3,485,399 shares of Common Stock outstanding as of January 27, 2020, as reported in the Issuer’s quarterly report on Form 10-K/A for the period ended September 30, 2019.
 
(a)
Amount Beneficially Owned
    See row 9 of cover page
     
 
(b)
Percent of Class
    See row 11 of cover page
     
 
(c)
Number of Shares as to which such person has
 
 
(i)
Sole power to vote or to direct the vote:
See row 5 of cover page
     
 
(ii)
Shared power to vote or to direct the vote:
See row 6 of cover page
     
 
(iii)
Sole power to dispose or to direct the disposition of:
See row 7 of cover page
     
 
(iv)
Shared power to dispose or to direct the disposition of:
See row 8 of cover page
 
 
CUSIP No. 03815U201
 SCHEDULE 13G
Page 5 of 6
 
Item 5.                  Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following box  ☐.
Item 6.                  Ownership of More than Five Percent on Behalf of Another Person
See Item 4.
Item 7.                  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
See Item 4.
Item 8.                  Identification and Classification of Members of the Group
Not Applicable.
Item 9.                  Notice of Dissolution of Group
Not Applicable.
Item 10. Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 
 
CUSIP No. 03815U201
 SCHEDULE 13G
Page 6 of 6
 
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.
Date:    February 6, 2020
 
/s/ Bruce Grossman
 
Name:  Bruce Grossman